Changing the way we find and treat cancer and rare diseases

Leading a new era in radiopharmaceuticals

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.

Telix’s deep pipeline for prostate, kidney, brain (glioblastoma), and hematologic cancers, and rare diseases is underpinned by a reliable and secure global supply chain, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA) and the US Food and Drug Administration (FDA) for its prostate cancer imaging agent and has more than 20 clinical trials underway worldwide.